HELIUS MEDICAL TECHNOLOGIES INC

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

HSDT$1.83-4.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share amounts)


		Years Ended December 31,

	2023		2022

Revenue
Product sales, net	$605			$778
Other revenue	39			9
Total revenue	644			787
Cost of revenue	583			463
Gross profit	61			324
Operating expenses
Selling, general and administrative expenses	9,271			10,640
Research and development expenses	2,942			4,262
Amortization expense	117			181
Goodwill and fixed asset impairment	159			757
Total operating expenses	12,489			15,840
Loss from operations	(12,428)			(15,516)
Nonoperating income (expense)
Interest income (expense), net	257			(834)
Change in fair value of derivative liability	2,966			3,027
Foreign exchange gain (loss)	275			(756)
Other income (expense), net	80			7
Nonoperating income (expense), net	3,578			1,444
Loss before provision for income taxes	(8,850)			(14,072)
Provision for income taxes	—			—
Net loss	(8,850)			(14,072)
Other comprehensive income (loss)
Foreign currency translation adjustments	(285)			737
Comprehensive loss	$(9,135)			$(13,335)
Loss per share
Basic	$(14.56)			$(52.13)
Diluted	$(14.56)			$(52.13)
Weighted average number of common shares outstanding
Basic	607,890			269,929
Diluted	607,890			269,929

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.